Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Standard

Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. / Nahi, Hareth; Genell, Anna; Wålinder, Göran; Uttervall, Katarina; Juliusson, Gunnar; Karin, Forsberg; Hansson, Markus; Svensson, Ronald; Linder, Olle; Carlson, Kristina; Björkstrand, Bo; Kristinsson, Sigurdur Y; Mellqvist, Ulf-Henrik; Blimark, Cecilie; Turesson, Ingemar.

I: European Journal of Haematology, Vol. 99, Nr. 3, 09.2017, s. 216-222.

Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

Harvard

Nahi, H, Genell, A, Wålinder, G, Uttervall, K, Juliusson, G, Karin, F, Hansson, M, Svensson, R, Linder, O, Carlson, K, Björkstrand, B, Kristinsson, SY, Mellqvist, U-H, Blimark, C & Turesson, I 2017, 'Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register', European Journal of Haematology, vol. 99, nr. 3, s. 216-222. https://doi.org/10.1111/ejh.12907

APA

CBE

Nahi H, Genell A, Wålinder G, Uttervall K, Juliusson G, Karin F, Hansson M, Svensson R, Linder O, Carlson K, Björkstrand B, Kristinsson SY, Mellqvist U-H, Blimark C, Turesson I. 2017. Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. European Journal of Haematology. 99(3):216-222. https://doi.org/10.1111/ejh.12907

MLA

Vancouver

Author

Nahi, Hareth ; Genell, Anna ; Wålinder, Göran ; Uttervall, Katarina ; Juliusson, Gunnar ; Karin, Forsberg ; Hansson, Markus ; Svensson, Ronald ; Linder, Olle ; Carlson, Kristina ; Björkstrand, Bo ; Kristinsson, Sigurdur Y ; Mellqvist, Ulf-Henrik ; Blimark, Cecilie ; Turesson, Ingemar. / Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register. I: European Journal of Haematology. 2017 ; Vol. 99, Nr. 3. s. 216-222.

RIS

TY - JOUR

T1 - Incidence, characteristics, and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedish Myeloma Register

AU - Nahi, Hareth

AU - Genell, Anna

AU - Wålinder, Göran

AU - Uttervall, Katarina

AU - Juliusson, Gunnar

AU - Karin, Forsberg

AU - Hansson, Markus

AU - Svensson, Ronald

AU - Linder, Olle

AU - Carlson, Kristina

AU - Björkstrand, Bo

AU - Kristinsson, Sigurdur Y

AU - Mellqvist, Ulf-Henrik

AU - Blimark, Cecilie

AU - Turesson, Ingemar

PY - 2017/9

Y1 - 2017/9

N2 - Solitary plasmacytoma (SP) and plasma cell leukemia (PCL) are uncommon (3-6%) types of plasma cell disease. The risk of progression to symptomatic multiple myeloma (MM) is probably important for the outcome of SP. PCL is rare and has a dismal outcome. In this study, we report on incidence and survival in PCL/SP, and progression to MM in SP, using the prospective observational Swedish Multiple Myeloma Register designed to document all newly diagnosed plasma cell diseases in Sweden since 2008. Both solitary bone plasmacytoma (SBP) (n=124) and extramedullary plasmacytoma (EMP) (n=67) have better overall survival (OS) than MM (n=3549). Progression to MM was higher in SBP than in EMP (35% and 7% at 2 years, respectively), but this did not translate into better survival in EMP. In spite of treatment developments, the OS of primary PCL is still dismal (median of 11 months, 0% at 5 years). Hence, there is a great need for diagnostic and treatment guidelines as well as prospective studies addressing the role for alternative treatment options, such as allogeneic stem cell transplantation and monoclonal antibodies in the treatment of PCL.

AB - Solitary plasmacytoma (SP) and plasma cell leukemia (PCL) are uncommon (3-6%) types of plasma cell disease. The risk of progression to symptomatic multiple myeloma (MM) is probably important for the outcome of SP. PCL is rare and has a dismal outcome. In this study, we report on incidence and survival in PCL/SP, and progression to MM in SP, using the prospective observational Swedish Multiple Myeloma Register designed to document all newly diagnosed plasma cell diseases in Sweden since 2008. Both solitary bone plasmacytoma (SBP) (n=124) and extramedullary plasmacytoma (EMP) (n=67) have better overall survival (OS) than MM (n=3549). Progression to MM was higher in SBP than in EMP (35% and 7% at 2 years, respectively), but this did not translate into better survival in EMP. In spite of treatment developments, the OS of primary PCL is still dismal (median of 11 months, 0% at 5 years). Hence, there is a great need for diagnostic and treatment guidelines as well as prospective studies addressing the role for alternative treatment options, such as allogeneic stem cell transplantation and monoclonal antibodies in the treatment of PCL.

KW - Multiple myeloma

KW - Plasma cell neoplasms

UR - http://www.scopus.com/inward/record.url?scp=85021440860&partnerID=8YFLogxK

U2 - 10.1111/ejh.12907

DO - 10.1111/ejh.12907

M3 - Article

VL - 99

SP - 216

EP - 222

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 1600-0609

IS - 3

ER -